Chapter 38 Quiz: Peptide Regulation

Twenty-two items. Multiple choice and short answer. The answer key follows, collapsed.

Reminder: this quiz tests your understanding of regulatory structures, which differ by jurisdiction and change over time. Nothing here is legal advice, and no correct answer tells anyone what they may lawfully buy, import, or possess.

1. An approval is best described as:

  • a) a certificate that a molecule is safe
  • b) a regulator's judgment that, for a specified indication and population, the evidence submitted shows benefits outweigh risks
  • c) confirmation that a drug is superior to available alternatives
  • d) a guarantee that all long-term effects are known

2. Which of the following is not one of the three consequences of the definition of approval given in §38.1?

  • a) approval is indication-specific
  • b) approval is based on the evidence submitted
  • c) approval is jurisdiction-specific
  • d) approval is permanent once granted

3. In the United States, an alpha-amino-acid polymer with a specific, defined sequence of more than 40 amino acids is regulated as:

  • a) a drug, approved through an NDA
  • b) a biological product, licensed through a BLA
  • c) a dietary supplement
  • d) a combination product

4. Insulin is __ amino acids across _ chains, and it was deemed a biological product under a statutory transition that took effect in ___.

5. Which follow-on pathway becomes available to a molecule on the biologic side of the line?

  • a) generics, via demonstrated bioequivalence
  • b) biosimilars, with a separate interchangeability determination available
  • c) neither; biologics have no follow-on pathway
  • d) both, at the sponsor's election

6. Semaglutide's peptide backbone is 31 residues. Which side of the line does it sit on, and what does that determine?

7. True or false: because insulin is heavier in daltons than semaglutide, it falls on the biologic side of the line.

8. An IND is:

  • a) an approval to market a drug
  • b) a permission to administer an investigational compound to human beings
  • c) a designation granted to drugs for rare diseases
  • d) the application reviewed before a biosimilar is licensed

9. Where in the development pathway is attrition most concentrated, and why?

10. Accelerated approval permits approval on a surrogate endpoint. What is required afterward, and what is the crucial word describing the status of that confirmatory evidence?

11. Name the five meanings of "not FDA approved."

12. Which of the five is a genuinely negative signal about the molecule itself?

  • a) never submitted
  • b) submitted and rejected
  • c) approved elsewhere, not here
  • d) not a drug at all in the regulatory sense

13. Which of the five applies to BPC-157 in the United States, as of this writing?

14. A peptide is a registered medicine in one country and unapproved in another. Name the two very different underlying stories that could produce this.

15. In the United States and many other jurisdictions, a licensed prescriber may prescribe an approved drug off-label, but a manufacturer may not promote off-label use. This asymmetry is best explained as:

  • a) an oversight in the statute
  • b) a deliberate design that preserves clinical freedom while keeping the evidentiary burden on the party that profits from the claim
  • c) a rule that applies only to controlled substances
  • d) a consequence of the biologics framework

16. Complete: "The label tells you what was __ and _. It does not tell you what is ___."

17. Which statement about 503A and 503B is correct?

  • a) 503B products receive premarket review of efficacy; 503A products do not
  • b) 503A facilities are subject to GMP requirements; 503B facilities are not
  • c) neither category involves premarket review of safety or efficacy
  • d) both categories require patient-specific prescriptions

18. Describe the shortage mechanism in one sentence: what a shortage listing permits, and what happens when the shortage is declared resolved.

19. "For research use only — not for human consumption" is best characterized as:

  • a) a regulatory category conferred by a health authority
  • b) a liability posture written by the seller
  • c) an exemption granted to registered laboratories
  • d) evidence that the compound is unstudied

20. DSHEA (1994) created a supplement category with no premarket approval requirement. What additional requirement must a substance still meet to be lawfully sold in that category?

21. State the S0 rule, and explain in one sentence why "it isn't on the banned list" is usually wrong by construction.

22. BPC-157 is rated ❌ for its healing claims and is prohibited under S0. Explain in two sentences why these facts are independent, and name what would change each one.

Answer key **1.** **(b).** The other three are the standard misreadings §38.1 warns about: approval is not a safety certificate, does not establish superiority over alternatives, and does not mean long-term effects are known. **2.** **(d).** Approvals are revisable. Drugs are withdrawn, labels revised, warnings added, and indications removed as evidence accumulates. **3.** **(b).** More than 40 amino acids means biological product, licensed through a Biologics License Application. Forty or fewer means drug, approved through a New Drug Application. **4.** **51** amino acids across **two** chains; deemed a biological product under a transition that took effect in **March 2020**. That transition is what opened the biosimilar pathway for insulin. **5.** **(b).** Biosimilars, a substantially more demanding and expensive route than a generic filing, with a separate interchangeability determination for pharmacy-level substitution. **6.** **The drug side** (31 is fewer than 40). It determines that follow-on competition, when exclusivity ends, will arrive through the **generic** pathway — abbreviated applications resting on demonstrated bioequivalence — rather than through the biosimilar pathway. Credit for noting that this connects to the access argument in Chapter 12 and the patent discussion in §36.9. **7.** **False.** The line counts amino acids in a defined sequence, not daltons. Semaglutide carries substantial non-amino-acid mass in its fatty acid chain and linker, which adds daltons without adding residues. Insulin is on the biologic side because it is 51 residues, not because it is heavier. **8.** **(b).** An Investigational New Drug application permits human administration. It is a permission to test, not an approval of anything, and press releases sometimes blur this. **9.** At the stage where **efficacy in humans is actually tested** — late Phase 2 and Phase 3. Everything before that stage is, in a precise sense, a prediction; Phase 2 and 3 are where the prediction meets a randomized comparison in the target population (Chapter 10). **10.** **Confirmatory trials** are required. The crucial word is **deferred** — confirmatory evidence is deferred, not waived. Full credit for connecting this to Chapter 16: the surrogate-endpoint problem is a designed feature of accelerated approval, not an incidental criticism of it. **11.** (1) Never submitted. (2) Submitted and rejected, or withdrawn after a negative review. (3) Approved elsewhere, not here. (4) Approved, but not for this use — off-label. (5) Not a drug at all in the regulatory sense: cosmetic ingredient, research reagent, or a product marketed as a supplement. **12.** **(b).** Only case (2) involves a regulator seeing a sponsor's best case and being unpersuaded. The other four say nothing about the molecule. **13.** **Case (1) — never submitted.** No application has been filed for approval as a drug. There is no rejection, no adverse finding on the merits, and no file. Note the discipline: Chapter 17's ❌ rests on the empty human literature, not on this. **14.** Either **the two agencies applied different evidence standards** to the same dossier and reached different conclusions, or **the sponsor simply never filed** in the second market — because it was small, or the regulatory cost was not worth it, or no local counterpart existed. Both are common; they are not equivalent; you cannot tell which applies without looking. **15.** **(b).** Medical practice moves faster than regulatory filings, and much well-supported prescribing rests on evidence no sponsor had commercial reason to submit. The burden is placed on the party with the strongest incentive to overstate. **16.** "The label tells you what was **submitted** and **approved**. It does not tell you what is **known**." **17.** **(c).** 503B brings GMP requirements and federal inspection — real and substantial oversight — but neither category involves a regulator's judgment that the product works or that benefits outweigh risks. That identical row is the most important one on the table. **18.** When a drug is on the official shortage list, compounding of what would otherwise be an essentially-a-copy product is **permitted in defined circumstances**; when the shortage is declared **resolved**, that permission **narrows** and compounders must wind down. This is the mechanism behind the large compounded GLP-1 market of the mid-2020s and its subsequent restriction — the details and timing of which were contested, including in litigation. **19.** **(b).** It is a sentence written by a seller for the seller's benefit. It transfers risk without changing what the product is, and no agency conferred it. Note that (d) is wrong for an interesting reason: the disclaimer is not evidence of anything about the compound at all. **20.** The substance must **qualify as a dietary ingredient**. DSHEA removed premarket approval; it did not make the category unlimited. Regulators have taken the position that certain synthetic peptides — **BPC-157 among them** — do not qualify, which means "sold as a supplement" can be not merely uninformative but incorrect as a classification claim. **21.** **S0 — Non-Approved Substances:** any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use is prohibited at all times. It is a **rule about a property**, not a list of names, so an unapproved compound is prohibited whether or not anyone has ever written its name down. Absence from a named list is therefore not evidence of being permitted. (Note: these rules bind athletes in tested sport; anyone subject to them should consult the current List, which is updated annually, rather than a textbook.) **22.** The **❌** is a judgment about the published human evidence for the healing claims — as of this writing, essentially absent. The **S0 prohibition** is a judgment about regulatory status, and it attaches *because* the compound is unapproved, with no clause anywhere about whether it works. A well-designed positive human trial would move the rating and leave the prohibition untouched; approval by a governmental health authority for human therapeutic use would remove it from S0's scope and, by itself, leave the rating where it was.